, Volume 62, Issue 6, pp 1094–1095 | Cite as

Underpowered or negative? A crucial distinction

  • Ole L. Dollerup
  • Jonas T. Treebak
  • Niels JessenEmail author


Clinical trial Human Hyperinsulinaemic–euglycaemic clamp Insulin sensitivity NAD+ metabolism Nicotinamide riboside 



Hyperinsulinaemic–euglycaemic clamp


Contribution statement

All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.


  1. 1.
    Connell NJ, Houtkooper RH, Schrauwen P (2019) NAD+ metabolism as a target for metabolic health: have we found the silver bullet? Diabetologia.
  2. 2.
    Dollerup OL, Christensen B, Svart M et al (2018) A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 108(2):343–353. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Inzucchi SE, Maggs DG, Spollett GR et al (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338(13):867–872. CrossRefPubMedGoogle Scholar
  4. 4.
    Malin SK, Haus JM, Solomon TPJ et al (2013) Insulin sensitivity and metabolic flexibility following exercise training among different obese insulin-resistant phenotypes. Am J Physiol Endocrinol Metab 305(10):E1292–E1298. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Integrative Physiology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  2. 2.Medical Research Laboratory, Department of Clinical MedicineAarhus UniversityAarhusDenmark
  3. 3.Steno Diabetes Center Aarhus (SDCA)Aarhus University Hospital and Central Denmark RegionAarhus NDenmark
  4. 4.Department of BiomedicineAarhus UniversityAarhusDenmark

Personalised recommendations